Pediatric Mixed-Phenotype Acute Leukemia: What's New?

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Sep 28

PMID 34572885

Citations 9

Authors

Sandeep Batra

Anthony John Ross

Affiliations

Soon will be listed here.

Abstract

Mixed-phenotype acute leukemias (MPAL) are rare in children and often lack consensus on optimal management. This review examines the current controversies and emerging paradigms in the management of pediatric MPAL. We examine risk stratification, outcomes of recent retrospective and prospective collaborative trials, and the role of transplantation and precision genomics, and outline emerging targets and concepts in this rare entity.

Citing Articles

Evolving Horizons in Pediatric Leukemia: Novel Insights, Challenges, and the Journey Ahead.

Tito Rodriguez P, Mehta D, Subhan M, Yadav R, Yousofzai B, Al-Najjar E Cureus. 2024; 16(8):e67480.

PMID: 39310608 PMC: 11415937. DOI: 10.7759/cureus.67480.

A hybrid protocol CLAG-M, a possible player for the first-line therapy of patients with mixed phenotype acute leukemia. A Polish Adult Leukemia Group experience.

Karasek M, Armatys A, Skarupski M, Bolkun L, Budziszewska K, Drozd-Sokolowska J Front Oncol. 2024; 14:1395992.

PMID: 38835383 PMC: 11148324. DOI: 10.3389/fonc.2024.1395992.

Biological Markers of High-Risk Childhood Acute Lymphoblastic Leukemia.

He J, Munir F, Catueno S, Connors J, Gibson A, Robusto L Cancers (Basel). 2024; 16(5).

PMID: 38473221 PMC: 10930495. DOI: 10.3390/cancers16050858.

The Outcome of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Experience from a Referral Center in South India.

Antonisamy N, Boddu D, John R, Korrapolu R, Balasubramanian P, Arunachalam A Indian J Hematol Blood Transfus. 2024; 40(1):61-67.

PMID: 38312177 PMC: 10830957. DOI: 10.1007/s12288-023-01684-9.

Genetic Characterization of Pediatric Mixed Phenotype Acute Leukemia (MPAL).

Panagopoulos I, Andersen K, Johannsdottir I, Tandsaether M, Micci F, Heim S Cancer Genomics Proteomics. 2023; 21(1):1-11.

PMID: 38151288 PMC: 10756350. DOI: 10.21873/cgp.20424.

References

Lazarus H, Richards S, Chopra R, Litzow M, Burnett A, Wiernik P . Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood. 2006; 108(2):465-72. PMC: 1895498. DOI: 10.1182/blood-2005-11-4666. View

Mansur M, Ford A, Emerenciano M . The role of RAS mutations in MLL-rearranged leukaemia: A path to intervention?. Biochim Biophys Acta Rev Cancer. 2017; 1868(2):521-526. DOI: 10.1016/j.bbcan.2017.10.005. View

Xiao W, Bharadwaj M, Levine M, Farnhoud N, Pastore F, Getta B . and mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. Blood Adv. 2018; 2(23):3526-3539. PMC: 6290101. DOI: 10.1182/bloodadvances.2018023531. View

Shimizu H, Yokohama A, Hatsumi N, Takada S, Handa H, Sakura T . Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era. Eur J Haematol. 2014; 93(4):297-301. DOI: 10.1111/ejh.12343. View

Takahashi K, Wang F, Morita K, Yan Y, Hu P, Zhao P . Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018; 9(1):2670. PMC: 6039465. DOI: 10.1038/s41467-018-04924-z. View

Oberley M, Raikar S, Wertheim G, Malvar J, Sposto R, Rabin K . Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. Leukemia. 2020; 34(7):1741-1750. PMC: 7332384. DOI: 10.1038/s41375-020-0741-0. View

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

Bachir F, Zerrouk J, Howard S, Graoui O, Lahjouji A, Hessissen L . Outcomes in patients with mixed phenotype acute leukemia in Morocco. J Pediatr Hematol Oncol. 2013; 36(6):e392-7. DOI: 10.1097/MPH.0b013e31828e54a5. View

Hu T, Murdaugh R, Nakada D . Transcriptional and Microenvironmental Regulation of Lineage Ambiguity in Leukemia. Front Oncol. 2017; 7:268. PMC: 5681738. DOI: 10.3389/fonc.2017.00268. View

10.

Durer S, Durer C, Shafqat M, Comba I, Malik S, Faridi W . Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. Immunotherapy. 2019; 11(5):373-378. PMC: 6439498. DOI: 10.2217/imt-2018-0104. View

11.

Mejstrikova E, Volejnikova J, Fronkova E, Zdrahalova K, Kalina T, Sterba J . Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria. Haematologica. 2010; 95(6):928-35. PMC: 2878790. DOI: 10.3324/haematol.2009.014506. View

12.

Manara E, Baron E, Tregnago C, Aveic S, Bisio V, Bresolin S . MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia. Blood. 2014; 124(2):263-72. DOI: 10.1182/blood-2013-09-525741. View

13.

Shain K, Dalton W, Tao J . The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene. 2015; 34(36):4673-82. PMC: 4688902. DOI: 10.1038/onc.2014.403. View

14.

Baeuerle P, Reinhardt C . Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009; 69(12):4941-4. DOI: 10.1158/0008-5472.CAN-09-0547. View

15.

Wood B . Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom. 2015; 90(1):47-53. DOI: 10.1002/cyto.b.21239. View

16.

Choi S, Frederiksen J, Ross C, Bixby D, Shao L . Philadelphia Chromosome-like Mixed-Phenotype Acute Leukemia Demonstrating P2RY8-CRLF2 Fusion and JAK1 Mutation. Am J Clin Pathol. 2017; 148(6):523-528. DOI: 10.1093/ajcp/aqx111. View

17.

Munker R, Labopin M, Esteve J, Schmid C, Mohty M, Nagler A . Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica. 2017; 102(12):2134-2140. PMC: 5709113. DOI: 10.3324/haematol.2017.174441. View

18.

Park J, Geyer M, Brentjens R . CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood. 2016; 127(26):3312-20. PMC: 4929923. DOI: 10.1182/blood-2016-02-629063. View

19.

Park J, Ghim T, Bae K, Im H, Jang S, Park C . Stem cell transplant in the treatment of childhood biphenotypic acute leukemia. Pediatr Blood Cancer. 2009; 53(3):444-52. DOI: 10.1002/pbc.22105. View

20.

Seetharam S, Thankamony P, Gopakumar K, Nair R, Jacob P, Krishna K . Outcomes of pediatric mixed phenotype acute leukemia treated with lymphoid directed therapy: Analysis of an institutional series from India. Pediatr Hematol Oncol. 2021; 38(4):358-366. DOI: 10.1080/08880018.2020.1871453. View